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ABSTRACT
Background: Metabolic syndrome has clinical implications for chronic liver disease, but the relationship between
chronic hepatitis B and metabolic syndrome remains unclear. The aim of this study was to determine whether
hepatitis B surface antigen (HBsAg) positivity is associated with metabolic syndrome.
Methods: Data were obtained from the Third Korean National Health and Nutrition Examination Survey
(KNHANES). Participant sera were tested for HBsAg. Metabolic syndrome was deﬁned according to the modiﬁed
National Cholesterol Education Program Adult Treatment Panel III guidelines for Koreans.
Results: Of the 5108 participants, 209 (4.1%) tested positive for HBsAg, and 1364 (26.7%) were diagnosed with
metabolic syndrome. The prevalence of metabolic syndrome was 23.4% in HBsAg-positive men, 31.5% in HBsAg-
negative men, 18.6% in HBsAg-positive women, and 23.7% in HBsAg-negative women. After adjusting for multiple
factors, male participants who tested positive for serum HBsAg had an odds ratio of 0.612 (95% conﬁdence interval
[CI] 0.375–0.998) for metabolic syndrome and an odds ratio of 0.631 (95% CI 0.404–0.986) for elevated
triglycerides. Women who tested positive for serum HBsAg had an odds ratio of 0.343 (95% CI 0.170–0.693) for
elevated triglycerides.
Conclusions: Positive results for serum HBsAg are inversely associated with metabolic syndrome in men and with
elevated triglycerides in men and women. This suggests that elevated triglycerides may contribute to the inverse
association between HBsAg and metabolic syndrome.
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INTRODUCTION
Chronic hepatitis B, which results from hepatitis B virus
(HBV) infection, is widespread in Korea. In 2009, the
prevalence of hepatitis B surface antigen (HBsAg), a marker
of HBV infection, was 3.2% in Korea.1 Chronic HBV infection
can lead to the development of liver cirrhosis and/or
hepatocellular carcinoma.2 The majority of chronic HBV
infections in Korea are acquired in the perinatal period, though
some HBV infections are acquired via horizontal transmission.
Metabolic syndrome, also known as insulin resistance
syndrome, is a constellation of metabolic disorders, including
increased waist circumference, hyperglycemia, elevated blood
pressure, and an abnormal lipid proﬁle. In Korea, the
prevalence of metabolic syndrome has increased markedly
in recent years, from 24.9% in 1998 to 31.3% in 2007.3
Metabolic syndrome is associated with liver diseases,
including non-alcoholic fatty liver disease, chronic hepatitis
C virus (HCV) infection, and hepatocellular carcinoma.
Non-alcoholic fatty liver disease is a hepatic manifestation
of metabolic syndrome.4 In chronic hepatitis C, metabolic
syndrome is a potential independent predictor of liver-related
mortality.5 Insulin resistance reduces the response to anti-
HCV treatment.6 Metabolic syndrome is a possible risk factor
for hepatocellular carcinoma, independent of the hepatitis
virus.4,7 However, to the best of our knowledge, there are
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few existing studies on the association between metabolic
syndrome and chronic hepatitis B. Three studies conducted
in Asian populations reported that chronic hepatitis B is
associated with a low prevalence of metabolic syndrome.8–10
However, the study populations were limited to small
geographic areas, which may have led to selection bias. In
addition, the statistical models used in these three studies were
not adjusted for all potentially confounding factors.
The Third Korean National Health and Nutrition
Examination Survey (KNHANES III) is a population-based
examination survey conducted in 2005 by the Korean Centers
for Disease Control and Prevention and the Korean Ministry
of Health and Welfare.11 KNHANES III was designed to yield
data representative of the Korean population. Thus, use of
KNHANES III data will hopefully prevent selection bias that
may have been unavoidable in the aforementioned studies
focused on smaller geographic areas.8–10
HBV is endemic to Korea, and the prevalence of metabolic
syndrome is also increasing in Korea.1,3 The aim of this study
was to use representative data from KNHANES III to
investigate the possible association between HBsAg and
metabolic syndrome and to determine if there are correlations
between HBsAg and components of metabolic syndrome,
including elevated blood pressure, elevated blood glucose,
elevated triglycerides, low high-density lipoprotein (HDL)
cholesterol, or increased waist circumference.
METHODS
Study population and data
The KNHANES III data used in this study included
anthropometric measurements, questionnaire responses, and
blood chemistry tests. Enrolled participants were ≥20 years of
age and underwent an examination including a test for serum
HBsAg, which was detected using an electrochemilumines-
cence immunoassay. A total of 5108 participants were selected
and their data analyzed. Approval of this study was obtained
from the Institutional Review Board of Myongji Hospital,
Goyang, Korea, complying with the Treaty of Helsinki.
Parameters and deﬁnitions
Metabolic syndrome was deﬁned based on the modiﬁed
criteria for Koreans from the National Cholesterol Education
Program Adult Treatment Panel III.12 Participants were
categorized into three groups by Korean districts according
to the population: large city, small-medium city, or rural area.
Subjects with a body mass index ≥25 kg/m2 were considered
obese. Increased waist circumference was deﬁned as a waist
circumference ≥90 cm in Korean men and ≥85 cm in Korean
women.13 Subjects were considered to have hypertension
when systolic blood pressure was ≥140mmHg, diastolic
blood pressure was ≥90mmHg, or they had a medical history
of antihypertensive drug use. Type 2 diabetes mellitus was
deﬁned as a fasting blood glucose ≥126mg/dL or a medical
history of hypoglycemia or insulin use. Subjects who had
smoked more than 100 cigarettes in their life were categorized
as smokers, while current alcohol consumption was deﬁned as
consumption of more than one glass of alcohol in the last year.
Planned, systematic, and repeated physical activity to improve
or maintain physical strength was considered regular exercise.
Income status was classiﬁed into ﬁve categories: <1 000 000
Korean Won/month, ≥1 000 000 and <2 000 000, ≥2 000 000
and <3 000 000, ≥3 000 000 and <4 000 000, and ≥4 000 000.
Education level was classiﬁed into ﬁve categories: none (did
not complete elementary school), only through elementary
school, only through middle school, only through high school,
and through college.
Statistical analysis
Chi-square tests and t-tests were used to assess differences
in anthropometric features, laboratory test results, personal
medical history, and health behaviors between participants
with and without chronic hepatitis B. Logistic regression
analysis was used to investigate the association between
chronic hepatitis B and metabolic syndrome. Logistic regres-
sion analysis was also used to investigate the associations
between chronic hepatitis B and the ﬁve components of
metabolic syndrome, including elevated triglycerides, elevated
blood pressure, elevated blood glucose, low HDL cholesterol,
and increased waist circumference. SPSS software version
11.0 (SPSS, Inc., Chicago, IL, USA) was used for analysis.
P-values <0.05 were considered statistically signiﬁcant.
RESULTS
Baseline characteristics of participants
A total of 5108 participants were analyzed, consisting of 2144
men and 2964 women (Table 1). Mean ± standard deviation
age was 47.1 ± 15.1 years. The prevalences of HBsAg
positivity and metabolic syndrome were 4.1% and 26.7%,
respectively. Of the 107 men participants who were HBsAg-
positive, 23.4% also had metabolic syndrome. Of the 2037
men participants who were HBsAg-negative, 31.5% had
metabolic syndrome. There was no signiﬁcant difference in
the prevalence of metabolic syndrome between HBsAg-
positive and HBsAg-negative men (P = 0.077). Of the ﬁve
components of metabolic syndrome, only prevalence of
elevated triglycerides was signiﬁcantly lower in HBsAg-
positive men than in HBsAg-negative men (29.0% vs. 38.5%,
P = 0.047). Of the 102 woman participants who were HBsAg-
positive, 18.6% had metabolic syndrome. Of the 2862 woman
participants who were HBsAg-negative, 23.7% had metabolic
syndrome. There was no signiﬁcant difference in the pre-
valence of metabolic syndrome between HBsAg-positive and
HBsAg-negative women (P = 0.233). Of the ﬁve components
of metabolic syndrome, only prevalence of elevated triglyc-
erides was signiﬁcantly lower in HBsAg-positive women than
in HBsAg-negative women (8.8% vs. 20.7%, P = 0.003).
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Serum HBsAg and metabolic syndrome
In a multivariate analysis, the odds ratio of a positive result
for HBsAg was 0.612 (95% conﬁdence interval [CI]
0.375–0.998) in men with metabolic syndrome and 0.695
(95% CI 0.400–1.208) in women with metabolic syndrome,
after adjusting for age, location, smoking habits, alcohol
consumption, exercise habits, income status, and education
level (Table 2).
Multivariable analyses were performed to explore the
associations between a positive result for HBsAg and the
ﬁve components of metabolic syndrome. The odds ratio for
elevated triglycerides was 0.631 in HBsAg-positive men
(95% CI 0.404–0.986) and 0.343 in HBsAg-positive women
(95% CI 0.170–0.693; Table 3). Elevated triglycerides were
inversely associated with HBsAg positivity.
DISCUSSION
Our study shows that serum HBsAg positivity is inversely
correlated with prevalence of metabolic syndrome in Korean
men but not in women. This is consistent with ﬁndings from
other Asian studies.8–10 A Taiwanese study reported that the
prevalence of metabolic syndrome was 8.0% in HBsAg-
positive subjects and 10.9% in HBsAg-negative subjects.8
Another study performed in China reported that the pre-
valence of metabolic syndrome was 5.9% in HBsAg-positive
participants and 8.8% in HBsAg-negative participants.10 In
both of these studies, this inverse association remained even
after adjusting for age and sex. A study performed in Hong
Kong reported that the prevalence of metabolic syndrome was
11.0% in patients with chronic hepatitis B and 20.2% in
controls without chronic hepatitis B.9 However, these three















Age (year)a 47.1 (15.1) 45.4 (12.5) 47.4 (14.6) 0.112 46.6 (13.5) 46.9 (15.5) 0.855
Gender (men), n (%) 2144 (42.0%) — — — —
Location (large city), n (%) 2201 (43.1%) 42 (39.3%) 696 (34.2%) 0.313 34 (33.3%) 963 (33.6%) 0.710
BMI (kg/m2)a 23.7 (3.3) 24.2 (3.0) 24.0 (3.1) 0.466 24.0 (3.7) 23.5 (3.4) 0.170
Systolic pressure (mmHg)a 119.1 (17.8) 119.6 (13.0) 123.0 (16.2) 0.011 118.7 (19.6) 116.3 (18.5) 0.201
Diastolic pressure (mmHg)a 77.3 (10.7) 79.2 (9.5) 80.9 (10.4) 0.106 75.7 (10.1) 74.7 (10.3) 0.328
Waist circumference (cm)a 81.0 (9.7) 84.6 (8.4) 84.3 (8.8) 0.790 79.5 (9.3) 78.5 (9.6) 0.263
AST (IU/L)b 22.0 [19.0–27.0] 27.0 [22.0–39.0] 24.0 [20.0–29.0] 0.000d 23.0 [20.8–29.0] 20.0 [17.0–24.0] <0.0001d
ALT (IU/L)b 18.0 [13.0–25.0] 30.0 [21.0–47.0] 22.0 [17.0–31.0] <0.0001d 18.0 [15.0–23.3] 15.0 [12.0–20.0] <0.0001d
Fasting blood glucose (mg/dL)b 90.0 [85.0–98.0] 91.0 [85.0–99.0] 92.0 [86.5–101.0] 0.331d 88.0 [83.0–96.3] 89.0 [84.0–96.0] 0.600d
Total cholesterol (mg/dL)b 183.0 [160.0–206.0] 179.0 [153.0–199.0] 184.0 [161.0–206.0] 0.050d 181.5 [156.0–201.3] 182.0 [160.0–206.0] 0.320d
HDL cholesterol (mg/dL)a 45.1 (10.8) 43.2 (10.3) 42.2 (10.1) 0.337 47.9 (10.6) 47.1 (10.9) 0.443
Triglyceride (mg/dL)b 105.0 [75.0–157.0] 106.0 [76.0–158.0] 126.0 [88.0–188.5] 0.011d 84.5 [65.0–109.3] 94.0 [68.0–136.0] 0.014d
Metabolic syndrome, n (%) 1364 (26.7%) 25 (23.4%) 641 (31.5%) 0.077 19 (18.6%) 679 (23.7%) 0.233
Elevated triglyceride, n (%) 1418 (27.8%) 31 (29.0%) 785 (38.5%) 0.047 9 (8.8%) 593 (20.7%) 0.003
Elevated blood pressure, n (%) 1860 (36.4%) 44 (41.4%) 938 (46.0%) 0.319 30 (29.4%) 848 (29.6%) 0.962
Elevated blood glucose, n (%) 1130 (22.1%) 25 (23.4%) 577 (28.3%) 0.266 16 (15.7%) 512 (17.9%) 0.568
Low HDL cholesterol, n (%) 2875 (56.3%) 48 (44.9%) 933 (45.8%) 0.849 63 (61.8%) 1831 (64.0%) 0.648
Abdominal obesity, n (%) 1306 (25.6%) 29 (27.1%) 539 (26.5%) 0.883 26 (25.5%) 712 (24.9%) 0.888
Hypertension, n (%) 1361 (26.6%) 30 (28.0%) 638 (31.3%) 0.475 23 (22.5%) 670 (23.4%) 0.840
Diabetes mellitus, n (%) 437 (8.6%) 9 (8.4%) 225 (11.0%) 0.394 7 (6.9%) 196 (6.8%) 0.995
Obesityc, n (%) 1665 (32.6%) 43 (40.2%) 728 (35.7%) 0.350 33 (32.4%) 861 (30.1%) 0.624
Smoking, n (%) 1934 (37.9%) 83 (77.6%) 1636 (80.3%) 0.488 3 (2.9%) 212 (7.4%) 0.087
Alcohol, n (%) 3287 (74.9%) 83 (77.6%) 1743 (85.6%) 0.023 63 (61.8%) 1938 (67.7%) 0.207
Exercise, n (%) 2432 (47.6%) 56 (52.3%) 1051 (51.6%) 0.881 43 (42.2%) 1282 (44.8%) 0.599
Income status, n (%) n = 5022 n = 103 n = 1999 0.315 n = 102 n = 2818 0.336
<1000000 Won 1269 (25.3%) 17 (16.5%) 472 (23.6%) 20 (19.6%) 760 (27.0%)
≥1000000 but <2000000 Won 1462 (29.1%) 34 (33.0%) 605 (30.3%) 36 (35.3%) 787 (27.0%)
≥2000000 but <3000000 Won 1196 (23.8%) 23 (22.3%) 480 (24.0%) 22 (21.6%) 671 (23.8%)
≥3000000 but <4000000 Won 517 (10.3%) 16 (15.5%) 213 (10.7%) 10 (9.8%) 278 (9.9%)
≥4000000 Won 578 (11.5%) 13 (12.6%) 229 (11.5%) 14 (13.7%) 322 (11.4%)
Education level, n (%) n = 5065 n = 107 n = 2018 0.089 99 2841 0.004
none 500 (9.9%) 2 (1.9%) 88 (4.4%) 11 (11.1%) 399 (14.0%)
only through elementary school 776 (15.3%) 6 (5.6%) 268 (13.3%) 15 (15.2%) 487 (17.1%)
only through middle school 590 (11.6%) 15 (14.0%) 239 (11.8%) 23 (23.2%) 313 (11.0%)
only through high school 1891 (37.3%) 43 (40.2%) 789 (39.1%) 35 (35.4%) 1024 (36.0%)
through college 1308 (25.8%) 41 (38.3%) 634 (31.4%) 15 (15.2%) 618 (21.8%)
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
aData are expressed as mean (SD).
bData are expressed as median [25–75 percentiles].
cObesity was deﬁned as body mass index ≥25kg/m2.
dP values were obtained using Mann-Whitney U test for skewed variables: AST, ALT, fasting glucose, total cholesterol, and triglyceride.
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studies did not stratify subjects by sex, as our study did. The
deﬁnition of metabolic syndrome differs according to sex,
and analysis should be performed separately for men and
women.12,13 Our study conducted separate analysis according
to sex and found that only HBsAg-positive males had a lower
prevalence of metabolic syndrome than their HBsAg-negative
counterparts. In addition, our study used a nationally
representative population, while the other studies did not.
In the present study, a positive result for serum HBsAg was
associated with a low prevalence of elevated triglycerides.
This low prevalence might be an important contributor to the
inverse association between HBsAg positivity and metabolic
syndrome, which would be consistent with ﬁndings in other
studies.9 Chen et al. reported that HBsAg positivity is
associated with lower prevalence of hypertriglyceridemia,14
while Su et al. reported that chronic hepatitis B is associated
with low serum levels of triglycerides.15 However, the exact
mechanism causing the low levels of triglycerides in HBsAg-
positive patients remains unclear. One study suggested that the
hepatitis B virus X protein is a contributor to low serum
triglycerides.16 The role of HBV in lipid metabolism should be
further explored.
Metabolic syndrome is related to liver ﬁbrosis. A cross-
sectional study in Taiwan reported that metabolic syndrome
increases the risk of liver cirrhosis in patients with chronic
hepatitis B.17 Metabolic syndrome has been linked to
increased risk and severity of liver ﬁbrosis through
activation of hepatic stellate cells.18 However, liver cirrhosis
itself can cause metabolic disturbances.19 These observations
suggest a relationship between HBV infection and diabetes
mellitus; development of diabetes mellitus may contribute
to secondary changes due to HBV infection but not to
HBV infection itself.20 In addition, hepatic ﬁbrosis in an
HBV-infected liver is caused by virus-induced liver injury
rather than insulin resistance.21 Thus, the cause and effect
relationship between metabolic syndrome and liver cirrhosis
in patients with chronic hepatitis B remains unclear.22
Chronic hepatitis C is associated with insulin resistance,
but the association between chronic hepatitis B and insulin
resistance is not well-established. Huang et al. reported that
chronic hepatitis B without cirrhosis is not associated with
type 2 diabetes mellitus.20 Kumar et al. reported that chronic
hepatitis B is not correlated with insulin resistance.23 On the
other hand, a study using NHANES III data reported that
type 2 diabetes mellitus and insulin resistance are independ-
ent predictors of overall mortality in chronic hepatitis B,
although only 66 participants in the study had chronic
hepatitis B.5
Table 2. Multivariate analysis of the association between positive HBsAg and metabolic syndrome
Model
Men (n = 2144) Women (n = 2964)
Odds ratio 95% CI P value Odds ratio 95% CI P value
Unadjusted 0.664 0.420–1.049 0.079 0.736 0.444–1.221 0.235
Model 1a 0.659 0.412–1.054 0.082 0.721 0.416–1.249 0.243
Model 2b 0.656 0.410–1.049 0.079 0.715 0.413–1.239 0.232
Model 3c 0.612 0.375–0.998 0.049 0.695 0.400–1.208 0.197
CI, conﬁdence interval.
aAdjusted for age.
bAdjusted for age, location and exercise habits.
cAdjusted for age, location, smoking habits, alcohol consumption, exercise habits, income status, and education levels.












Men (n = 2144)
Positive HBsAga
Odds ratio 0.631 0.856 0.803 0.915 1.042
95% CI 0.404–0.986 0.558–1.314 0.491–1.314 0.608–1.376 0.660–1.645
P value 0.043 0.477 0.382 0.670 0.860
Women (n = 2964)
Positive HBsAga
Odds ratio 0.343 1.037 0.840 0.862 1.014
95% CI 0.170–0.693 0.623–1.725 0.476–1.483 0.569–1.305 0.624–1.648
P value 0.003 0.890 0.548 0.482 0.955
CI, conﬁdence interval.
aAdjusted for age, location, smoking habits, alcohol consumption, exercise habits, income status, and education level.
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Our study had several limitations. First, various conditions
associated with HBsAg were not considered because the
KNHANES tested only for the presence of HBsAg and
hepatitis B surface antibody. An individual who is HBsAg-
positive may be a healthy carrier, have chronic active
hepatitis, or have liver cirrhosis. In terms of serology,
HBsAg positivity is associated with various levels of HBV
DNA concentration and two states of hepatitis B e antigen.
Further stratiﬁcation of HBsAg states should be performed to
determine the exact role of HBsAg in the development of
metabolic syndrome.
Second, the KNHANES did not differentiate between liver
cirrhosis and chronic hepatitis. Liver cirrhosis is closely
related to glucose intolerance, regardless of its cause.19
Diabetes may develop as a complication of cirrhosis, which
is called hepatogenous diabetes.24 Therefore, liver cirrhosis
may have contributed to the metabolic derangement observed
in our study. In addition, two recent studies reported
conﬂicting results on the association between metabolic
syndrome and liver cirrhosis in chronic hepatitis B
patients.17,21 One of these studies reported that metabolic
syndrome increases the risk of liver cirrhosis in chronic
hepatitis B patients.17 However, the other reported that hepatic
ﬁbrosis in HBV-infected liver is caused by virus-induced liver
injury, rather than by insulin resistance.21 The data suggest
that metabolic syndrome is not a risk factor for liver cirrhosis
but an outcome of liver cirrhosis.21 Therefore, liver cirrhosis
must be excluded when clarifying the effect of HBsAg on
metabolic syndrome.
Third, our study was a cross-sectional study, and therefore
it was not possible to explore a causal relationship between
chronic HBV infection and metabolic syndrome. It is unclear
whether chronic HBV infection suppresses development of
metabolic syndrome. In addition, horizontal transmission
could not be completely excluded from subjects with
chronic infection resulting from vertical transmission; in this
situation, chronic hepatitis B infection could have been
followed by development of metabolic syndrome.
In conclusion, data from KNHANES III indicate that
HBsAg positivity is associated with a low prevalence of
metabolic syndrome in men, and this association may be
partly attributed to low prevalence of elevated triglycerides.
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